REGENICS AS #pharma #logo

Posted On Aug 12 2017 by

#biotechnology companies


Board of directors

Tore Heldrup Rasmussen. MBA, Founder, Chairman of the Board. Mr. Rasmussen has been heading up several successful biotechnology companies prior to co-founding Regenics. Mr. Rasmussen brings many years of experience in strategy development and consumer products, as a Partner in MarkUp Consulting in Oslo and through tenures with Procter & Gamble and Orkla Foods (Norway). Mr. Rasmussen has an MBA degree from the University of Michigan.

Harald Nordal. MSc, MBA. Mr. Nordal serves on the Regenics Board of Directors and is the managing Director of Life Capitol AS, a Norwegian based holding company located in Hovdebygda, Norway, and a shareholder of Regenics. Mr. Nordal has a strong technical and managerial experience from the international operations of several Norwegian-based companies including Senior Project Manager of the oil and energy company StatoilHydro, Vice President of the technology and ship building company, Ulstein International, and Technical Director of Kv�rner Kleven. Prior to joining Life Capitol, Mr. Nordal held a position as Senior Vice President of the Norway division of Innovation Norway, promoting business development and cluster initiatives and as Project Director of the group�s global strategy development. He has served on the board of the seed money capital fund SIM and initiated other regional seed money initiatives. Mr. Nordal holds a MSc degree from the Norwegian University of Science and Technology, Trondheim, Norway and a MBA from CERAM, France.

Philippe Collas. PhD, Founder, Director and Scientific Adviser. Dr. Collas serves on the Regenics Board of Directors. He is Professor at the Institute of Medical Biochemistry of the University of Oslo, Norway, where he directs a laboratory of 20 people. Dr. Collas holds an engineering degree from France and a PhD from the University of Massachusetts. He has tremendous experience in research on nuclear reprogramming from academia (University of Massachusetts, Amherst College, University of Oslo) and industry in the United States. He was a co-founder of Nucleotech LLC (USA) and has served as Consultant for several Biotech Companies in Europe, United States and Australia. He has developed cell-free systems to investigate nuclear dynamics and gene function and has published over 100 scientific articles in the area of nuclear reprogramming. He was the first to show that somatic cells can be reprogrammed using cellular extracts. Dr. Collas is member of the Norwegian Academy of Science and Letters.

Runhild Gammels�ter. PhD. Dr. Gammels�ter serves on the Regenics Board of Directors and holds a PhD in cell physiology from the Faculty of Medicine at the University of Oslo. While working in the Neurotransmitter lab of the Centre of Molecular Biology and Neuroscience at the University of Oslo, she has investigated the physiology and cellular signaling of insulin-producing pancreatic islet cells for the past five years. She is also well-versed in the area of nuclear and cell reprogramming. As a Fulbright scholar, Dr. Gammels ter conducted research and held guest lectures at Joslin Diabetes Center of Harvard (Boston, MA), UCSF (San Francisco, CA) and Virginia Commonwealth University (Richmond, VA. Additionally, she has studied psychology at the University of Oslo and the University of Washington and has completed courses in leadership, motivation, and scientific journalism.

Biotechnology, cosmetics, wound healing

Cosmetic and therapeutic wound healing products for skin

Technology and ingredients for cosmetics and pharma

Market Position:
Gain market leadership in skin applications through IPR, product technology and development

Regenics is a private biotechnology company with a range of national investors. Regenics� research is partly funded by government grants from the Norwegian Research Council (BIA, SkatteFUNN) and Innovation Norway (IFU).

Last Updated on: August 12th, 2017 at 1:19 am, by

Written by admin

Leave a Reply

Your email address will not be published. Required fields are marked *